The company has emerged from stealth with funding from GV and New Enterprise Associates.

Duke spinout Precision BioSciences, whose investors include Amgen and Baxter, has raised an initial $88m in series B funding out of a $110m target.

Duke spinout Precision BioSciences, whose investors include Amgen and Baxter, has raised an initial $88m in series B funding out of a $110m target.

Investors in the series B round included FAW, Contemporary Amperex Technology and TUS Holdings.

The customer engagement software developer has raised $60m from investors including GV, the early-stage investment arm of Alphabet that previously supported a $32m series A.

Kunlun-backed Nashwork has attracted $78m in a series B+ round backed by Sino-Ocean Group.

Taikang Life and Lilly Asia Ventures, which backed the initial $59.7m series B round last year, have also contributed to a $35m series B+ round of Hangzhou Just Biotherapeutics.

Existing shareholder UMC Capital has returned to back a $13m series B round for NextInput.